Pneumoconiosis Guidelines
Pneumoconiosis Treatment Guidelines

Pneumoconiosis Treatment Guidelines

The specific guidelines for pneumoconiosis treatment vary from patient to patient. Generally speaking, treatment focuses on managing symptoms, preserving lung function and improving quality of life, since there is not presently a cure for pneumoconiosis.

Pneumoconiosis is an occupational lung disease that develops as a result of frequent, prolonged exposure to and inhalation of irritants like coal dust, silica and iron particles. Black lung disease (coal worker’s pneumoconiosis), silicosis and siderosis (welder’s lung) are the main forms of pneumoconiosis. Treatment guidelines for patients with these conditions often include:

  • Supplemental oxygen therapy – When the lungs alone aren’t able to supply an adequate amount of oxygen, receiving supplemental liquid oxygen or compressed oxygen gas through a face mask or nasal prongs can improve breathing and ease symptoms.
  • Bronchodilators – These medicines are used to help open up lung passages and improve breathing.
  • Not smoking – Smoking and other forms of tobacco use can exacerbate pneumoconiosis and cause additional health problems.
  • Avoiding exposure to harmful dusts and particles – It is important to avoid the substance that has led to pneumoconiosis, as continued exposure can worsen the disease and its symptoms.

The Lung Institute – the first cellular therapy center in the world to focus exclusively on pulmonary disease – offers cellular therapy as an alternative form of care for pneumoconiosis patients. This innovative therapy has the potential to reduce symptoms, ease lung inflammation and slow the progression of pneumoconiosis. Cellular therapy leverages the natural healing abilities of the patient’s own cells to help enhance lung function and improve quality of life.

Contact the Lung Institute at 888-745-6697 to learn more about our innovative treatment guidelines for pneumoconiosis and other forms of interstitial lung disease. A member of our medical team can answer any questions you may have about cellular therapy and help determine if you are a potential candidate for treatment at the Lung Institute.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.